| |
| |
|
| Insider
Information: |
Vaishnaw Akshay |
| Relationship: |
President |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
22,774 |
|
|
Indirect Shares
|
515 |
|
|
| Direct
Value |
$5,469,176 |
|
|
|
Indirect Value
|
$123,677 |
|
|
| Total
Shares |
23,289 |
|
|
| Total
Value |
$5,592,853 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -26.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alnylam Pharmaceuticals Inc |
ALNY |
President |
2023-08-04 |
22,774 |
2023-08-04 |
515 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
96 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D |
• – – |
2017-12-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
320 |
11,215 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2018-03-14 |
4 |
AS |
$140.45 |
$12,672,126 |
D/D |
(88,554) |
11,215 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2020-02-07 |
4 |
AS |
$125.00 |
$2,963,500 |
D/D |
(23,708) |
11,215 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2021-06-18 |
4 |
AS |
$175.00 |
$2,573,900 |
D/D |
(14,708) |
11,215 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2021-08-09 |
4 |
AS |
$200.00 |
$2,166,800 |
D/D |
(10,834) |
11,215 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2021-12-23 |
4 |
AS |
$186.22 |
$549,698 |
D/D |
(2,879) |
11,215 |
0 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D |
• – – |
2017-06-13 |
4 |
D |
$74.31 |
$31,953 |
D/D |
(430) |
11,535 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D |
• – – |
2017-10-30 |
4 |
AS |
$119.79 |
$4,088,967 |
D/D |
(33,666) |
11,535 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D |
• – – |
2017-06-13 |
4 |
OE |
$18.66 |
$32,007 |
D/D |
1,668 |
11,965 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2018-08-13 |
4 |
D |
$90.95 |
$69,668 |
D/D |
(766) |
12,173 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
SVP, Chief Medical Officer |
• – – |
2012-07-16 |
4 |
AS |
$19.00 |
$688,750 |
D/D |
(36,250) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2012-09-10 |
4 |
AS |
$19.00 |
$25,346 |
D/D |
(1,334) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2012-09-12 |
4 |
AS |
$19.00 |
$93,404 |
D/D |
(4,916) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2012-11-30 |
4 |
AS |
$17.03 |
$48,072 |
D/D |
(2,823) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2012-12-04 |
4 |
AS |
$17.04 |
$40,896 |
D/D |
(2,400) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2012-12-10 |
4 |
AS |
$17.00 |
$81,209 |
D/D |
(4,777) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2012-12-12 |
4 |
AS |
$19.00 |
$190,000 |
D/D |
(10,000) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-03-11 |
4 |
AS |
$24.55 |
$153,415 |
D/D |
(6,250) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-06-11 |
4 |
AS |
$31.07 |
$466,137 |
D/D |
(15,000) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-09-10 |
4 |
AS |
$57.39 |
$359,238 |
D/D |
(6,250) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-12-16 |
4 |
AS |
$60.19 |
$905,298 |
D/D |
(15,000) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2013-12-17 |
4 |
AS |
$60.59 |
$1,127,761 |
D/D |
(18,480) |
12,588 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2018-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,724 |
12,939 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
• – – |
2012-09-10 |
4 |
OE |
$9.30 |
$12,406 |
D/D |
1,334 |
13,922 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
• – – |
2021-12-22 |
4 |
D |
$186.48 |
$479,690 |
D/D |
(2,538) |
14,094 |
0 |
- |
|
96 Records found
|
|
Page 2 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
